Yes, iron deficiency anemia commonly causes thrombocytosis (elevated platelet count)
Iron deficiency anemia frequently leads to reactive thrombocytosis, occurring in approximately one-third of IDA patients, and this association carries clinically significant thrombotic risk that should not be dismissed as benign.
Mechanism and Prevalence
Iron deficiency anemia triggers thrombocytosis through multiple mechanisms. The platelet count elevation is reactive rather than clonal, distinguishing it from primary myeloproliferative disorders. Thrombocytosis occurs in 32.6% of patients with IDA 1, though the degree of elevation varies widely—from mild increases above 450 × 10⁹/L to extreme thrombocytosis exceeding 1,000 × 10⁹/L 2, 3.
The correlation between severity of anemia and platelet elevation is well-established. As hemoglobin decreases, platelet counts increase proportionally 1. This relationship appears mediated through:
- Increased platelet mass index that correlates negatively with hemoglobin levels
- Potential cross-reactivity between erythropoietin (EPO) and thrombopoietin receptors, though cytokine studies show inconsistent results 4
- Enhanced megakaryocyte production in bone marrow 3
Clinical Significance: Not a Benign Finding
The thrombotic risk associated with IDA-related thrombocytosis is substantial and clinically meaningful:
- Patients with IDA and thrombocytosis have a 2-fold increased risk of thrombosis compared to IDA patients without thrombocytosis (15.8% vs 7.8%) 1
- IDA alone increases VTE risk by 75% within one year (HR 1.75,95% CI: 1.58-1.94) 5
- Pulmonary embolism risk is particularly elevated (HR 2.05) compared to deep vein thrombosis (HR 1.54) 5
- Peak thrombotic risk occurs within the first 3 months after IDA diagnosis (HR 2.09) 5
Documented Thrombotic Complications
Real-world complications include:
- Central retinal vein occlusion 3
- Upper extremity thrombosis (2.5-fold increased risk) 5
- Recurrent pulmonary embolism and deep vein thrombosis 6
- Increased ICU admission rates (HR 1.67) and mortality (HR 2.12) 5
Distinguishing Reactive from Primary Thrombocytosis
When encountering thrombocytosis with IDA, differentiate reactive from clonal causes:
Features suggesting reactive thrombocytosis due to IDA:
- Microcytic, hypochromic anemia present
- Low ferritin (<12-15 μg/dL, or <100 μg/dL in inflammatory states) 7
- Increased bone marrow megakaryocytes without dysplasia 3
- Rapid platelet count normalization with iron replacement (typically within 1-3 months) 3, 4
Features requiring evaluation for myeloproliferative neoplasm:
- Thrombocytosis persisting despite iron repletion
- Splenomegaly
- JAK2, CALR, or MPL mutations
- Abnormal bone marrow morphology
Management Algorithm
1. Confirm Iron Deficiency
- Serum ferritin <12 μg/dL is diagnostic 7
- If ferritin 12-100 μg/dL with inflammation/malignancy, check transferrin saturation <20% 8, 9
- Document microcytosis (MCV <80 fL) and hypochromia 7, 10
2. Identify Underlying Cause
In men and postmenopausal women, gastrointestinal blood loss is the primary cause 7:
- Perform upper endoscopy with small bowel biopsies (to exclude celiac disease) 7
- Perform colonoscopy or CT colonography 11
- Check stool for occult blood 8
In premenopausal women aged <50 years 11:
- Screen for celiac disease (tissue transglutaminase antibodies)
- Reserve GI investigation for: upper GI symptoms, lower GI symptoms, strong family history of colorectal cancer, or persistent IDA after iron supplementation
3. Initiate Iron Replacement
Oral iron therapy 11:
- Ferrous sulfate 200 mg (65 mg elemental iron) 2-3 times daily
- Continue for 3 months after hemoglobin normalizes to replenish stores
- Expect platelet count normalization within 1-3 months 3, 4
Intravenous iron indications 11:
- Intolerance to oral iron
- Malabsorption (celiac disease, inflammatory bowel disease, post-bariatric surgery)
- Chronic kidney disease on dialysis
- Need for rapid correction
4. Monitor Response
- Check CBC at 1 month, 3 months, then 3-monthly for 1 year 11
- Platelet count should decline as hemoglobin rises 3, 4
- If thrombocytosis persists despite iron repletion, evaluate for myeloproliferative disorder
Thromboprophylaxis Considerations
The decision to anticoagulate is nuanced:
- Reactive thrombocytosis from IDA does not automatically require anticoagulation if no thrombotic event has occurred
- Iron replacement therapy reverses the hypercoagulable state 12, making it the primary intervention
- Consider thromboprophylaxis in high-risk scenarios:
When thrombocytosis-mediated thrombosis is excluded (by excluding patients who developed thrombocytosis), VTE risk is substantially attenuated (HR 1.19 vs 1.75), confirming that reactive thrombocytosis mediates much of the excess thrombotic risk 5.
Common Pitfalls
- Assuming thrombocytosis is always benign in IDA: The 2-fold increased thrombotic risk is clinically significant 1
- Initiating cytoreductive therapy before excluding IDA: Always check iron studies before treating thrombocytosis 2
- Inadequate iron repletion duration: Continue iron for 3 months after hemoglobin normalizes to replenish stores 11
- Missing post-bariatric surgery patients: These patients have chronic malabsorption requiring regular monitoring 2
- Failing to investigate GI causes in men and postmenopausal women: Occult malignancy may present as IDA 7
Special Populations
Chronic kidney disease: Absolute iron deficiency defined as transferrin saturation ≤20% with ferritin ≤100 μg/L (predialysis) or ≤200 μg/L (hemodialysis); requires nephrology co-management 9, 13
Chronic heart failure: Iron deficiency (ferritin <100 μg/L or transferrin saturation <20%) present in 40-70%; intravenous iron has prognostic benefit 9
Inflammatory bowel disease: Ferritin up to 100 μg/L may still reflect iron deficiency due to inflammation; oral iron ≤100 mg elemental iron daily 9